We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $17.59, marking a +1.62% move from the previous day. The stock outpaced the S&P 500's daily loss of 2.06%. Meanwhile, the Dow lost 1.76%, and the Nasdaq, a tech-heavy index, lost 2.39%.
Shares of the infectious disease drug developer have depreciated by 12.93% over the course of the past month, underperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 1.63%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 3.66% rise in the Zacks Consensus EPS estimate. Right now, Adma Biologics possesses a Zacks Rank of #2 (Buy).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 20.36. This signifies a premium in comparison to the average Forward P/E of 18.39 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 38% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $17.59, marking a +1.62% move from the previous day. The stock outpaced the S&P 500's daily loss of 2.06%. Meanwhile, the Dow lost 1.76%, and the Nasdaq, a tech-heavy index, lost 2.39%.
Shares of the infectious disease drug developer have depreciated by 12.93% over the course of the past month, underperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 1.63%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $0 million, indicating changes of +16.33% and 0%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 3.66% rise in the Zacks Consensus EPS estimate. Right now, Adma Biologics possesses a Zacks Rank of #2 (Buy).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 20.36. This signifies a premium in comparison to the average Forward P/E of 18.39 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 38% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.